Latest News
09-06-2019
Seny Liu received the Excellent Poster Award at the 16th Symposium of the Frontiers of Biomedical Sciences. Congratulations!
08-26-2019
Dr. Hu received the 15th Young Scholar Award from the TienTe Lee Biomedical Foundation.
06-27-2019
Our work on gelated cell technology for anticancer T cell expansion received the Best Poster Award at the 2019 Gordon Research Conference on cancer nanotechnology. Congratulations!
06-15-2019
Seny Liu obtained her Ph.D. with the highest honors (#1 rank) from her graduating class. Congratulations Dr. Liu.
06-11-2019
Saborni received the Academia Sinica Travel Grant Award to attend the 2019 Gordon Research Conference on Cancer Nanotechnology. Congratulations!
04-20-2019
Dr. Hu is co-appointed as an investigator by the Research Center for Applied Nanomedicine at the National Cheng Kung University.
03-29-2019
Dr. Hu received the Excellent Young Investigator Award and Sherry Tsai received the Best Poster Award at the 2019 Annual Meeting of Biomaterials and Controlled Releases Society in Taiwan. Congratulations!
03-27-2019
Our lab's international collaboration work on a MERS-CoV nanoparticle vaccine for emerging disease prevention is accepted for publication by Advanced Functional Materials.
02-19-2019
Our lab's work on a novel intracellular hydrogelation technology is accepted for publication by Nature Communications.
12-26-2018
Seny Liu successfully defended her Ph.D. thesis and became the first Ph.D. graduate from the lab. Congratulations!!!
Che-Ming Jack Hu (胡哲銘）
Associate Research Fellow
Institute of Biomedical Sciences, Academia Sinica
Dr. Jack Hu recevied his Ph.D. in Biomedical Engineering from the University of California, San Diego in 2011 and recevied postdoctoral trainings in the Nanoengineering Department of UCSD. He holds a B.S. degree in Biomedical Engineering with minors in Mechanical Engineering and Electrical Engineering from UC Berkeley.
Research Focus
Nanotechnology in medicine has shown tremendous value in drug delivery and vaccine preparations, where pharmacokinetics and immune activation can be finely tuned via rational nanomaterials engineering. The research focus of the laboratory is to develop novel therapeutic nanomaterials with an emphasis toward clinical translation. We seek to adopt an engineering approach to improve treatments for major diseases including cardiovascular disease, cancer, and infectious disease.
